Rani Therapeutics (RANI) director receives 123,600 stock options at $0.9515 strike

Rhea-AI Filing Summary

Rani Therapeutics Holdings director Dennis A. Ausiello received a grant of stock options covering 123,600 shares of Class A common stock. The options have an exercise price of $0.9515 per share and expire on May 27, 2036. This is a compensation-related award rather than an open-market purchase.

The options vest in full on the first anniversary of the grant date, subject to Dr. Ausiello’s continuous service. Vesting can occur earlier if either the company’s next annual stockholder meeting or a Change in Control happens while he remains in continuous service. Following this grant, he holds options for 123,600 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ausiello Dennis A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	123,600	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 123,600 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 123,600 shares Exercise price: $0.9515 per share Expiration date: May 27, 2036 +2 more

5 metrics

Option grant size 123,600 shares Director stock option award for Class A Common Stock

Exercise price $0.9515 per share Strike price of Director Stock Option

Expiration date May 27, 2036 Option term end for Director Stock Option

Post-grant derivative holdings 123,600 options Total derivative securities held following transaction

Vesting schedule 1-year cliff, with earlier vesting on certain events Vests after one year, or earlier on annual meeting or Change in Control

Key Terms

Director Stock Option, Class A Common Stock, 2021 Equity Incentive Plan, Continuous Service, +1 more

5 terms

Director Stock Option financial

"security_title: Director Stock Option (Right to Buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

2021 Equity Incentive Plan financial

"defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")"

Continuous Service financial

"subject to the Reporting Person's Continuous Service through such vesting date"

Change in Control financial

"upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ausiello Dennis A

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.9515	05/28/2026		A		123,600		(1)	05/27/2036	Class A Common Stock	123,600	$0	123,600	D

Explanation of Responses:

1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

	/s/ Svai Sanford, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did director Dennis A. Ausiello acquire in this RANI Form 4 filing?

Dennis A. Ausiello received a grant of stock options for 123,600 shares of Rani Therapeutics Class A common stock. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.

What is the exercise price of Dennis Ausiello’s RANI stock options?

The granted stock options carry an exercise price of $0.9515 per share. This means Dr. Ausiello can later buy up to 123,600 Rani Therapeutics Class A shares at $0.9515, subject to the options vesting and remaining unexpired through their 2036 expiration.

When do Dennis Ausiello’s Rani Therapeutics options vest?

The options vest in full on the first anniversary of the grant date, if Dennis Ausiello maintains Continuous Service. Vesting can occur earlier upon the next annual stockholder meeting or a qualifying Change in Control, provided he remains in Continuous Service under the 2021 Equity Incentive Plan.

When do Dennis Ausiello’s RANI stock options expire?

The stock options granted to Dennis Ausiello expire on May 27, 2036. After that date, any unexercised options become worthless, so they must be exercised before expiration, assuming vesting conditions and other plan requirements have been satisfied under the company’s 2021 Equity Incentive Plan.

How many RANI derivative securities does Dennis Ausiello hold after this grant?

After this grant, Dennis Ausiello holds options for 123,600 shares of Class A common stock. The filing’s summary shows this as his total derivative position related to this award, all held directly, with no additional remaining derivative positions listed in the derivative summary section.